Idelalisib | CAL-101;GS-1101;GS-1101, Idelalisib. | PI3K

首页 / / / PI3K / Idelalisib/艾代拉里斯

Idelalisib/艾代拉里斯 {[allProObj[0].p_purity_real_show]}

货号：A134749 同义名： CAL-101; GS-1101

Idelalisib（CAL-101；GS-1101）是一种高度选择性且口服生物利用度的p110δ抑制剂，IC50为2.5 nM，相对于其他I类PI3K酶展示了40至300倍的选择性。

Idelalisib/艾代拉里斯化学结构
CAS号：870281-82-6

Idelalisib/艾代拉里斯 3D分子结构
CAS号：870281-82-6

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Idelalisib/艾代拉里斯纯度/质量文件产品仅供科研

货号：A134749 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

PI3K 亚型比较

产品名称	C2β ↓ ↑	p110α ↓ ↑	p110β ↓ ↑	p110γ ↓ ↑	p110δ ↓ ↑	PI3K ↓ ↑	Vps34 ↓ ↑	其他靶点	纯度
A66	+ C2β, IC50: 462 nM	++ p110α, IC50: 32 nM							99%+
Taselisib	+ C2β, IC50: 292 nM	++++ PI3Kα, Ki: 0.29 nM	+++ PI3Kβ, Ki: 9.1 nM	++++ PI3Kγ, Ki: 0.97 nM	++++ PI3Kδ, Ki: 0.12 nM		+ hVps34, IC50: 374 nM		99%+
Gedatolisib		++++ PI3Kα, IC50: 0.4 nM		+++ PI3Kγ, IC50: 5.4 nM				mTOR	99%
HS-173		++++ PI3Kα , IC50: 0.8 nM							99%+
Serabelisib		+++ PI3Kα, IC50: 21 nM							99%+
GNE-477		++++ PI3Kα, IC50: 4 nM						mTOR	99%
YM-201636		+ p110α, IC50: 3.3 μM						PIKfyve	98%
AS-252424		+ PI3Kα, IC50: 935 nM		++ PI3Kγ, IC50: 33 nM					99%
Alpelisib		+++ PI3Kα, IC50: 5 nM							99%+
AS-604850		+ PI3Kα, IC50: 4.5 μM		+ PI3Kγ, IC50: 0.25 μM					99%
SF2523		++ PI3Kα, IC50: 34 nM		++ PI3Kγ, IC50: 158 nM				mTOR,DNA-PK	99%+
Inavolisib		++++ PI3K alpha, IC50: 0.038 nM							99%+
Bimiralisib		++++ PI3Kα, Kd: 1.5 nM	+++ PI3Kβ, Kd: 11 nM	++ PI3Kγ, Kd: 25 nM	++ PI3Kδ, Kd: 25 nM			mTOR	99%+
GSK1059615		++++ PI3Kα, IC50: 0.4 nM	++++ PI3Kβ, IC50: 0.6 nM	+++ PI3Kγ, IC50: 5 nM	++++ PI3Kδ, IC50: 2 nM			mTOR	98%
GSK2636771			✔						99%
Fimepinostat		+++ PI3Kα, IC50: 19 nM	++ PI3Kβ, IC50: 54 nM		++ PI3Kδ, IC50: 39 nM				99%+
VS-5584		++++ PI3Kα, IC50: 2.6 nM	+++ PI3Kβ, IC50: 21 nM	++++ PI3Kγ, IC50: 3.0 nM	++++ PI3Kδ, IC50: 2.7 nM			mTOR	98%
Dactolisib		++++ p110α1, IC50: 4 nM	++ p110β, IC50: 75 nM	+++ p110γ, IC50: 5 nM	+++ p110δ, IC50: 7 nM				98+%
PI-103		++++ p110α, IC50: 2 nM	++++ p110β, IC50: 3 nM	+++ p110γ, IC50: 15 nM	++++ p110δ, IC50: 3 nM			mTOR,DNA-PK	99%+
PI-3065			+ p110β, IC50: 1078 nM		+++ p110δ, IC50: 15 nM				99%+
Voxtalisib		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 113 nM	+++ PI3Kγ, IC50: 9 nM	++ PI3Kδ, IC50: 43 nM			mTOR,DNA-PK	99%+
AZD-8835		+++ PI3Kα, IC50: 6.2 nM	+ PI3Kβ, IC50: 431 nM	++ PI3Kγ, IC50: 90 nM	+++ PI3Kδ, IC50: 5.7 nM				99%
Pilaralisib analogue		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 36 nM	+++ PI3Kγ, IC50: 23 nM	++ PI3Kδ, IC50: 36 nM				99%+
ZSTK474		+++ PI3Kα, IC50: 16 nM	++ PI3Kβ, IC50: 44 nM	++ PI3Kγ, IC50: 49 nM	+++ PI3Kδ, IC50: 4.6 nM	++ PI3K, IC50: 37 nM			98%
AS-605240		++ PI3Kα, IC50: 60 nM	+ PI3Kβ, IC50: 270 nM	+++ PI3Kγ, IC50: 8 nM	+ PI3Kδ, IC50: 300 nM				98%
TGX-221			+++ p110β, IC50: 5 nM		++ p110δ, IC50: 0.1 μM				99%+
PF-04691502		++++ PI3Kα, Ki: 1.8 nM	++++ PI3Kβ, Ki: 2.1 nM	++++ PI3Kγ, Ki: 1.9 nM	++++ PI3Kδ, Ki: 1.6 nM			mTOR	98+%
GDC-0084		++++ PI3Kα, Ki app: 2 nM	++ PI3Kβ, Ki app: 46 nM	+++ PI3Kγ, Ki app: 10 nM	++++ PI3Kδ, Ki app: 3 nM			mTOR	99%+
Buparlisib		++ p110α, IC50: 52 nM	+ p110β, IC50: 166 nM	+ p110γ, IC50: 262 nM	++ p110δ, IC50: 116 nM		+ Vps34, IC50: 2.4 μM	mTOR	98%
LY294002		+ p110α, IC50: 0.5 μM	+ p110β, IC50: 0.97 μM		+ p110δ, IC50: 0.57 μM			DNA-PK	99%+
AZD 6482		+ PI3Kα, IC50: 870 nM	+++ PI3Kβ, IC50: 10 nM		++ PI3Kδ, IC50: 80 nM			DNA-PK	99%+
Pictilisib		++++ p110α, IC50: 3 nM	++ p110β, IC50: 33 nM	++ p110γ, IC50: 75 nM	++++ p110δ, IC50: 3 nM			mTOR	99%+
PKI-402		++++ PI3Kα, IC50: 2 nM	+++ PI3Kβ, IC50: 7 nM	+++ PI3Kγ, IC50: 16 nM	+++ PI3Kδ, IC50: 14 nM			mTOR	98%
Copanlisib		++++ PI3Kα, IC50: 0.5 nM	++++ PI3Kβ, IC50: 3.7 nM	+++ PI3Kγ, IC50: 6.4 nM	++++ PI3Kδ, IC50: 0.7 nM				99%+
Omipalisib		++++ p110α, Ki: 0.019 nM	++++ p110β, Ki: 0.13 nM	++++ p110γ, Ki: 0.06 nM	++++ p110δ, Ki: 0.024 nM				99%+
Izorlisib		+++ PI3Kα, IC50: 14 nM	++ PI3Kβ, IC50: 0.12 μM	++ PI3Kγ, IC50: 36 nM	+ PI3Kδ, IC50: 0.50 μM				99%+
AZD8186		++ PI3Kα, IC50: 35 nM	++++ PI3Kβ, IC50: 4 nM		+++ PI3Kδ, IC50: 12 nM				99%
KU-0060648		++++ PI3Kα, IC50: 4 nM	++++ PI3Kβ, IC50: 0.5 nM	+ PI3Kγ, IC50: 0.59 μM	++++ PI3Kδ, IC50: 0.1 nM			DNA-PK	98%
Apitolisib		+++ p110α, IC50: 5 nM	++ p110β, IC50: 27 nM	+++ p110γ, IC50: 14 nM	+++ p110δ, IC50: 7 nM			mTOR	98%+
CZC24832			+ PI3Kβ, IC50: 1.1 μM	++ PI3Kγ, IC50: 27 nM					98+%
BGT226 maleate		++++ PI3Kα, IC50: 4 nM	++ PI3Kβ, IC50: 63 nM	++ PI3Kγ, IC50: 38 nM				mTOR	99%+
TG 100713		++ PI3Kα, IC50: 165 nM	+ PI3Kβ, IC50: 215 nM	++ PI3Kγ, IC50: 50 nM	+++ PI3Kδ, IC50: 24 nM				98%+
PI3K-IN-1		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 113 nM	+++ PI3Kγ, IC50: 9 nM	++ PI3Kδ, IC50: 43 nM			mTOR,DNA-PK	98+%
TG100-115		+ PI3Kα, IC50: 1.3 μM	+ PI3Kβ, IC50: 1.2 μM	++ PI3Kγ, IC50: 83 nM	+ PI3Kδ, IC50: 235 nM				98%
PIK-90		+++ PI3Kα, IC50: 11 nM	+ PI3Kβ, IC50: 350 nM	+++ PI3Kγ, IC50: 18 nM	++ PI3Kδ, IC50: 58 nM				99%+
PIK-294			+ p110β, IC50: 490 nM	++ p110γ, IC50: 160 nM	+++ p110δ, IC50: 10 nM				99%+
Duvelisib			++++ PI3Kβ, Ki: 1564 pM	++ PI3Kγ, Ki: 243 pM	++++ PI3Kδ, Ki: 23 pM				99%+
GDC-0326		++++ PI3Kα, Ki: 0.2 nM	++ PI3Kβ, Ki: 26.6 nM	+++ PI3Kγ, Ki: 10.2 nM	++++ PI3Kδ, Ki: 4 nM				98%
Quercetin Dihydrate			+ PI3Kβ, IC50: 5.4 μM	+ PI3Kγ, IC50: 2.4 μM	+ PI3Kδ, IC50: 3.0 μM				95%
Quercetin			+ PI3Kβ, IC50: 5.4 μM	+ PI3Kγ, IC50: 2.4 μM	+ PI3Kδ, IC50: 3.0 μM			Src,Sirtuin,PKC	95%
Leniolisib		+ PI3Kα, IC50: 0.244 μM	+ PI3Kβ, IC50: 0.424 μM	+ PI3Kγ, IC50: 2.23 μM	+++ PI3Kδ, IC50: 0.011 μM			DNA-PK	99%+
PIK-108			✔						99%
Eganelisib				+++ PI3Kγ, IC50: 16 nM					99%+
CAY10505				✔					99%
IPI-3063					++++ p110δ, IC50: 2.5 nM				99%
Nemiralisib					++++ PI3Kδ, pKi: 9.9				99%+
PF-4989216		++++ p110α, IC50: 2 nM		++ p110γ, IC50: 65 nM	++++ p110δ, IC50: 1 nM				99%+
PIK-75 HCl		+++ p110α, IC50: 5.8 nM		++ p110γ, IC50: 76 nM	+ p110δ, IC50: 0.51 μM			DNA-PK	99%+
Tenalisib				++ PI3Kγ, IC50: 33.2 nM	++ PI3Kδ, IC50: 24.5 nM				98%
Acalisib					+++ p110δ, IC50: 14 nM				99%+
Umbralisib					+++ PI3Kδ, IC50: 22.2 nM				99%+
AMG319				+ PI3Kγ, IC50: 850 nM	+++ PI3Kδ, IC50: 18 nM				99%
IC-87114				+ PI3Kγ, IC50: 29 μM	+ PI3Kδ, IC50: 0.5 μM				99%+
Idelalisib				++ p110γ, IC50: 89 nM	++++ p110δ, IC50: 2.5 nM				98%
PIK-293				+ p110γ, IC50: 10 μM	+ p110δ, IC50: 0.24 μM				99%+
Vps34-PIK-III					+ PI3Kδ, IC50: 1.2μM		+++ Vps34, IC50: 0.018μM		99%+
GSK2292767					✔				98%
Seletalisib				+ PI3Kγ, IC50: 282 nM	+++ PI3Kδ, IC50: 12 nM				99%+
P110δ-IN-1					++++ P110δ, IC50: 0.6 nM				99%
PI3Kδ-IN-5					++++ PI3Kδ, IC50: 0.9 nM				99%
SRX3207		+ PI3K alpha, IC50: 244 nM		+ PI3K gamma, IC50: 9790 nM	+ PI3K delta, IC50: 388 nM			Syk	98%
Parsaclisib HCl					++++ PI3Kδ, IC50: 1 nM				98%
IHMT-PI3Kδ-372					+++ PI3Kδ, IC50: 14 nM				98%
Trigonelline						✔		Akt	99%+
Wortmannin						++++ PI3K, IC50: 3 nM		MLCK,DNA-PK	99%+
Samotolisib						✔		DNA-PK	99%+
GNE-317						✔			99%+
Oroxin B						✔		Akt,PTEN	99%+
NU 7026						+ PI3K, IC50: 13 μM		DNA-PK	98+%
Deguelin						✔		Akt	99%+
Ailanthone						✔		Akt,ATM/ATR,CDK	98%
Resibufogenin						✔		ROS	98%
KU-57788						+ PI3K, IC50: 5 μM		mTOR,DNA-PK	99%+
Cinobufagine						✔		Akt	99%
α-Linolenic acid						✔			97% (GC)
MTX-211						✔		EGFR	98%
PI3K/mTOR Inhibitor-2						++++ PI3K, IC50: 3.4 nM		mTOR	99%+
SPP-86						✔			99%+
(E)-Akt inhibitor-IV						✔			98%
Vps34-IN-1							++ Vps34, IC50: 25 nM		98%
SAR405							++++ Vps34, IC50: 1.2 nM		98+%
3-Methyladenine				+ PI3Kγ, IC50: 60 μM			+ Vps34, IC50: 25 μM	Autophagy	98%
Vps34-IN-4							+++ VPS34, IC50: 15 nM		98%+
Autophinib							+++ Vps34, IC50: 19 nM	Autophagy	99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Idelalisib/艾代拉里斯生物活性

靶点	p110γ p110γ, IC50:89 nM p110δ p110δ, IC50:2.5 nM
描述	PI3Ks are lipid kinases participating in several cellular process. There are eight PI3Ks, which have been identified as classes IA, 1B, II and III based on the sequence homology and substrate preference. The class IA PI3K is a heterodimer consisting of a 110 kDa catalytic subunit (p110α, p110β and p110δ), and an 85 kDa regulatory subunit^[2]. CAL-101 is an orally available and selective inhibitor of p110δ (IC50=2.5nM, analyzed using the SelectScreen kinase inhibitor assay service) with less potent to p110γ (IC50=89nM). In SU-DHL-5, KARPAS-422 and B-ALL (CCRF-SB) cell lines, CAL-101 can produce a concentration-dependent reduction in pAktS473, pAktT308 and the downstream target S6 and also induce apoptosis significantly^[1]. It has also been found that CAL-101 can induce caspase-dependent death of malignant CLL cells, suppresse the production of protumor cytokine by T and NK cells, as well as abrogate prosurvival microenvironmental signals like B-cell activating factor, tumor necrosis factor and fibronectin^[3]. Thus, CAL-101 has effects both on tumor microenvironment and directly on tumors. Now CAL-101 has been used in monotherapy studies in patients with non-Hodgkin lymphoma (Phase1/2)^[4].
作用机制	Idelalisib can bind to the ATP-binding pocket of PI3Kδ, which is responsible for the selectivity for PI3Kδ.^[5]

Idelalisib/艾代拉里斯细胞实验

Cell Line Maver-1 Z-138 SUM159 BT549 murine thymocytes HCT-116 cells Huh-BAT HepG2 MEC1 cells CLL cells Human platelets Human platelets	Concentration	Treated Time	Description	References
Maver-1	1 μM	8 hours	To analyze the effect of combination therapy on gene expression in Maver-1 cells. Results showed that combination therapy significantly altered the gene expression profile.	Acta Pharmacol Sin. 2022 Feb;43(2):457-469
Z-138	2 μM	96 hours	To evaluate the effect of A-485 combined with idelalisib on the proliferation of Z-138 cells. Results showed that A-485 significantly enhanced the sensitivity to idelalisib.	Acta Pharmacol Sin. 2022 Feb;43(2):457-469
SUM159	25 μM	96 h	To test the growth inhibitory effect of Idelalisib on TNBC cells	Breast Cancer Res. 2019 Feb 1;21(1):20.
BT549	25 μM	96 h	To test the growth inhibitory effect of Idelalisib on TNBC cells	Breast Cancer Res. 2019 Feb 1;21(1):20.
murine thymocytes	10 µM		To investigate the effect of Idelalisib on thymocyte respiration, results showed that Idelalisib had no significant effect on thymocyte respiration	Exp Hematol Oncol. 2016 Jul 29;5:22.
HCT-116 cells	10 μM	48 h	Inhibition of PIK3CD significantly suppressed the growth, migration, and invasion of HCT-116 cells.	Cancer Sci. 2019 Mar;110(3):997-1011.
Huh-BAT	20 μM	48 h	Suppressed HCC cell proliferation and induced cell cycle arrest, reduced cell invasion, upregulated E-cadherin expression, and downregulated N-cadherin and Snail expression.	Clin Mol Hepatol. 2020 Oct;26(4):529-539.
HepG2	20 μM	48 h	Suppressed HCC cell proliferation and induced cell cycle arrest, reduced cell invasion, upregulated E-cadherin expression, and downregulated N-cadherin and Snail expression.	Clin Mol Hepatol. 2020 Oct;26(4):529-539.
MEC1 cells	2 μM	5 days	To investigate the effect of Idelalisib on Rictor and pAktS473 levels in MEC1 cells, results showed upregulation of Rictor and pAktS473 levels.	J Clin Invest. 2024 Oct 22;134(23):e173770.
CLL cells	1 μM	48 h	To investigate the effect of Idelalisib on Akt phosphorylation in CLL cells, results showed inhibition of Akt phosphorylation.	J Clin Invest. 2024 Oct 22;134(23):e173770.
Human platelets	10 µM	10 min	To evaluate the inhibitory effect of PI3K inhibitors on intracellular calcium release induced by the GPVI-specific agonist CRP, results showed that Idelalisib significantly inhibited calcium release.	Int J Mol Sci. 2021 Mar 24;22(7):3304.
Human platelets	10 µM	10 min	To assess the potential toxicity of Idelalisib on platelet viability using Calcein-AM flow cytometry, results showed that platelets remained highly viable after Idelalisib treatment.	Int J Mol Sci. 2021 Mar 24;22(7):3304.

Idelalisib/艾代拉里斯动物实验

Species Mice Nude mice Mice Mice Nude mice	Animal Model C57BL/6 mice HCT-116 xenograft model ITK-SYKCD4-CreERT2;PD-1-/- mice FeCl3-induced arterial thrombosis model HCT 116 xenograft model	Administration	Dosage	Frequency	Description	References
Mice	C57BL/6 mice	Intraperitoneal injection	2.5 µg/g	Once daily for 4 days	To investigate the effect of Idelalisib on thymus size, results showed that Idelalisib had no significant effect on thymus size	Exp Hematol Oncol. 2016 Jul 29;5:22.
Nude mice	HCT-116 xenograft model	Oral	30 mg/kg/d	Once daily for 10 days	Inhibition of PIK3CD significantly suppressed the growth of HCT-116 xenograft tumors.	Cancer Sci. 2019 Mar;110(3):997-1011.
Mice	ITK-SYKCD4-CreERT2;PD-1-/- mice	Oral	10 mg/kg	5 days a week for 5 days	To study the effect of PI3K inhibition on ITK-SYK+PD-1-/- lymphoma mice, results showed that PI3K inhibition significantly extended the lifespan of these mice.	Nature. 2017 Dec 7;552(7683):121-125
Mice	FeCl3-induced arterial thrombosis model	Oral administration	20 mg/kg	Single dose, experiments performed 1 hour after administration	To evaluate the antithrombotic effect of Idelalisib in the FeCl3-induced arterial thrombosis model, results showed that Idelalisib significantly prolonged the occlusion time, indicating its antithrombotic potential.	Int J Mol Sci. 2021 Mar 24;22(7):3304.
Nude mice	HCT 116 xenograft model	Intragastric administration	15 mg/kg	Once daily for 21 days	To evaluate the antitumor effect of Idelalisib in vivo on KRAS-mutant colorectal cancer, the results showed that Idelalisib significantly inhibited tumor growth without obvious hepatotoxicity or renal toxicity.	Cell Death Dis. 2024 Jul 3;15(7):474

Idelalisib/艾代拉里斯动物研究

Dose	Mice: min = 10 mg/kg^[6], max = 40 mg/kg^[7]
Administration	p.o, i.v, i.p

Idelalisib/艾代拉里斯临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03310190	-		Recruiting	June 15, 2020	Canada, Alberta ... 展开 >> University of Calgary /ID# 166416 Recruiting Calgary, Alberta, Canada, T2N 4Z6 Cross Cancer Institute /ID# 166417 Not yet recruiting Edmonton, Alberta, Canada, T6G 1Z2 Canada, New Brunswick The Moncton Hospital /ID# 166043 Recruiting Moncton, New Brunswick, Canada, E1C 6Z8 Saint John Regional Hospital /ID# 202190 Not yet recruiting Saint John, New Brunswick, Canada, E2L 4L2 Canada, Ontario William Osler Health System /ID# 202049 Not yet recruiting Brampton, Ontario, Canada, L6R 3J7 Michael Garron Hospital/Toronto East Health Network /ID# 209463 Not yet recruiting East York, Ontario, Canada, M4C 3E7 Kingston Health Sciences Centr /ID# 169252 Recruiting Kingston, Ontario, Canada, K7L 2V7 The Ottawa Hospital Research /ID# 166041 Recruiting Ottawa, Ontario, Canada, K1H 8L6 Health Sciences North /ID# 205817 Recruiting Sudbury, Ontario, Canada, P3N 1H5 Canada, Quebec Jewish General Hospital /ID# 166418 Recruiting Montreal, Quebec, Canada, H3T 1E2 Cisss Du Bas-Saint-Laurent Hopital Regional de Rimouski /Id# 201202 Recruiting Rimouski, Quebec, Canada, G5L 5T1 Canada CancerCare Manitoba /ID# 170751 Recruiting Manitoba, Canada, R3E 0V9 Thunder Bay Regional Health Re /ID# 204740 Not yet recruiting Thunder Bay, Canada, P7B 6V4 收起 <<
NCT03283137	CLL B-cell No... 展开 >>n Hodgkin Lymphoma 收起 <<	Phase 1	Recruiting	December 2020	United States, Illinois ... 展开 >> University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Michael Thirman, MD mthirman@medicine.bsd.uchicago.edu Contact: Howard Weiner 7737022084 hweiner@medicine.bsd.uchicago.edu 收起 <<
NCT02141282	Chronic Lymphocytic Leukemia	Phase 2	Active, not recruiting	December 8, 2021	United States, California ... 展开 >> Ucsd /Id# 128535 La Jolla, California, United States, 92037 University of California, Los Angeles /ID# 127262 Los Angeles, California, United States, 90095 Stanford Univ School of Med /ID# 126495 Stanford, California, United States, 94305-2200 United States, District of Columbia Medstar Georgetown Univ Med Ct /ID# 127261 Washington, District of Columbia, United States, 20007 United States, Georgia Emory University Hospital /ID# 131249 Atlanta, Georgia, United States, 30322 United States, Illinois Northwestern University /ID# 126497 Chicago, Illinois, United States, 60611-2927 United States, Massachusetts Beth Israel Deaconess Med Ctr /ID# 134509 Boston, Massachusetts, United States, 02215-5400 Dana-Farber Cancer Institute /ID# 126496 Boston, Massachusetts, United States, 02215 United States, Minnesota Mayo Clinic - Rochester /ID# 130013 Rochester, Minnesota, United States, 55905-0001 United States, New York Columbia Univ Medical Center /ID# 128536 New York, New York, United States, 10032-3725 New York Presbyterian Hospital - Weill Cornell Medical Center /ID# 129648 New York, New York, United States, 10032-3725 Univ Rochester Med Ctr /ID# 130011 Rochester, New York, United States, 14642 United States, Ohio The Ohio State University - Columbus /ID# 127263 Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pennsylvania /ID# 126860 Philadelphia, Pennsylvania, United States, 19104-5502 United States, Texas Univ TX, MD Anderson /ID# 126498 Houston, Texas, United States, 77030 United States, Utah University of Utah /ID# 129984 Salt Lake City, Utah, United States, 84112-5500 University of Utah /ID# 130813 Salt Lake City, Utah, United States, 84112-5500 收起 <<

Idelalisib/艾代拉里斯参考文献

[1]Lannutti BJ, Meadows SA, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011 Jan 13;117(2):591-4.

[2]Zhao HF, Wang J, et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer. 2017 Jun 7;16(1):100.

[3]Herman SE, Gordon AL, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010 Sep 23;116(12):2078-88.

[4]Cheah CY, Fowler NH, et al. Idelalisib in the management of lymphoma. Blood. 2016 Jul 21;128(3):331-6.

[5]Berndt A, Miller S, et al. The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol. 2010 Feb;6(2):117-24.

[6]Ahmad S, Abu-Eid R, et al. Differential PI3Kδ Signaling in CD4⁺ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy. Cancer Res. 2017;77(8):1892-1904.

[7]Low PC, Manzanero S, et al. PI3Kδ inhibition reduces TNF secretion and neuroinflammation in a mouse cerebral stroke model. Nat Commun. 2014.

Idelalisib/艾代拉里斯实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.41mL

0.48mL

0.24mL

12.04mL

2.41mL

1.20mL

24.07mL

4.81mL

2.41mL

Idelalisib/艾代拉里斯技术信息

CAS号	870281-82-6
分子式	C₂₂H₁₈FN₇O
分子量	415.42
SMILES Code	O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)CC)=NC5=C1C(F)=CC=C5
MDL No.	MFCD19443647

别名	CAL-101; GS-1101; GS-1101, Idelalisib.
运输	蓝冰
InChI Key	IFSDAJWBUCMOAH-HNNXBMFYSA-N
Pubchem ID	11625818

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, 2-8°C

溶解方案

细胞实验：

DMSO: 60 mg/mL(144.43 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03310190	-		Recruiting	June 15, 2020	Canada, Alberta ... 展开 >> University of Calgary /ID# 166416 Recruiting Calgary, Alberta, Canada, T2N 4Z6 Cross Cancer Institute /ID# 166417 Not yet recruiting Edmonton, Alberta, Canada, T6G 1Z2 Canada, New Brunswick The Moncton Hospital /ID# 166043 Recruiting Moncton, New Brunswick, Canada, E1C 6Z8 Saint John Regional Hospital /ID# 202190 Not yet recruiting Saint John, New Brunswick, Canada, E2L 4L2 Canada, Ontario William Osler Health System /ID# 202049 Not yet recruiting Brampton, Ontario, Canada, L6R 3J7 Michael Garron Hospital/Toronto East Health Network /ID# 209463 Not yet recruiting East York, Ontario, Canada, M4C 3E7 Kingston Health Sciences Centr /ID# 169252 Recruiting Kingston, Ontario, Canada, K7L 2V7 The Ottawa Hospital Research /ID# 166041 Recruiting Ottawa, Ontario, Canada, K1H 8L6 Health Sciences North /ID# 205817 Recruiting Sudbury, Ontario, Canada, P3N 1H5 Canada, Quebec Jewish General Hospital /ID# 166418 Recruiting Montreal, Quebec, Canada, H3T 1E2 Cisss Du Bas-Saint-Laurent Hopital Regional de Rimouski /Id# 201202 Recruiting Rimouski, Quebec, Canada, G5L 5T1 Canada CancerCare Manitoba /ID# 170751 Recruiting Manitoba, Canada, R3E 0V9 Thunder Bay Regional Health Re /ID# 204740 Not yet recruiting Thunder Bay, Canada, P7B 6V4 收起 <<
NCT03283137	CLL B-cell No... 展开 >>n Hodgkin Lymphoma 收起 <<	Phase 1	Recruiting	December 2020	United States, Illinois ... 展开 >> University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Michael Thirman, MD mthirman@medicine.bsd.uchicago.edu Contact: Howard Weiner 7737022084 hweiner@medicine.bsd.uchicago.edu 收起 <<
NCT02141282	Chronic Lymphocytic Leukemia	Phase 2	Active, not recruiting	December 8, 2021	United States, California ... 展开 >> Ucsd /Id# 128535 La Jolla, California, United States, 92037 University of California, Los Angeles /ID# 127262 Los Angeles, California, United States, 90095 Stanford Univ School of Med /ID# 126495 Stanford, California, United States, 94305-2200 United States, District of Columbia Medstar Georgetown Univ Med Ct /ID# 127261 Washington, District of Columbia, United States, 20007 United States, Georgia Emory University Hospital /ID# 131249 Atlanta, Georgia, United States, 30322 United States, Illinois Northwestern University /ID# 126497 Chicago, Illinois, United States, 60611-2927 United States, Massachusetts Beth Israel Deaconess Med Ctr /ID# 134509 Boston, Massachusetts, United States, 02215-5400 Dana-Farber Cancer Institute /ID# 126496 Boston, Massachusetts, United States, 02215 United States, Minnesota Mayo Clinic - Rochester /ID# 130013 Rochester, Minnesota, United States, 55905-0001 United States, New York Columbia Univ Medical Center /ID# 128536 New York, New York, United States, 10032-3725 New York Presbyterian Hospital - Weill Cornell Medical Center /ID# 129648 New York, New York, United States, 10032-3725 Univ Rochester Med Ctr /ID# 130011 Rochester, New York, United States, 14642 United States, Ohio The Ohio State University - Columbus /ID# 127263 Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pennsylvania /ID# 126860 Philadelphia, Pennsylvania, United States, 19104-5502 United States, Texas Univ TX, MD Anderson /ID# 126498 Houston, Texas, United States, 77030 United States, Utah University of Utah /ID# 129984 Salt Lake City, Utah, United States, 84112-5500 University of Utah /ID# 130813 Salt Lake City, Utah, United States, 84112-5500 收起 <<
NCT02742090	Chronic Lymphocytic Leukemia	Phase 2	Active, not recruiting	December 2019	United States, District of Col... 展开 >>umbia TG Therapeutics Investigational Trial Site Washington, District of Columbia, United States, 20007 United States, Florida TG Therapeutics Investigational Trial Site Fort Myers, Florida, United States, 33916 TG Therapeutics Investigational Trial Site Saint Petersburg, Florida, United States, 33705 United States, Missouri TG Therapeutics Investigational Trial Site Kansas City, Missouri, United States, 64132 United States, New Hampshire TG Therapeutics Investigational Trial Site Lebanon, New Hampshire, United States, 03756 United States, New Jersey TG Therapeutics Investigational Trial Site Hackensack, New Jersey, United States, 07601 United States, New York TG Therapeutics Investigational Trial Site New Hyde Park, New York, United States, 11042 TG Therapeutics Investigational Trial Site New York, New York, United States, 10032 TG Therapeutics Investigational Trial Site Rochester, New York, United States, 14642 United States, North Carolina TG Therapeutics Investigational Trial Site Durham, North Carolina, United States, 27710 United States, Pennsylvania TG Therapeutics Investigational Trial Site Hershey, Pennsylvania, United States, 17033 TG Therapeutics Investigational Trial Site Philadelphia, Pennsylvania, United States, 19146 United States, Tennessee TG Therapeutics Investigational Trial Site Nashville, Tennessee, United States, 37203 United States, Washington TG Therapeutics Investigational Trial Site Seattle, Washington, United States, 98104 收起 <<
NCT01644253	Chronic Lymphocytic Leukemia ... 展开 >> Peripheral T-cell Lymphoma 收起 <<	Phase 1	Active, not recruiting	December 2019	United States, Georgia ... 展开 >> Augusta, Georgia, United States, 30912 United States, Ohio Columbus, Ohio, United States, 43210 United States, South Carolina Greenville Health System Greenville, South Carolina, United States, 29605 United States, Texas Houston, Texas, United States, 77030 United States, Washington Swedish Cancer Institute,1221 Madison St. Seattle, Washington, United States, 98104 收起 <<
NCT02457598	B-cell Malignancies	Phase 1	Active, not recruiting	May 2022	United States, District of Col... 展开 >>umbia Georgetown University Medical Center Washington, District of Columbia, United States, 20007 United States, Indiana Indiana University Health Goshen Center for Cancer Care Goshen, Indiana, United States, 46506 United States, Oregon Oregon Health and Science University Portland, Oregon, United States, 97239 France CHRU de Lille, Hopital Claude Huriez Lille, France, 59037 Hopital Saint Eloi Montpellier, France, 34295 Chu Haut Leveque Pessac, France, 33604 Centre Hospitalier de Lyon Sud Pierre Benite, France, 69310 Institut Universitaire du Cancer-Oncopole I.U.C.T-O Toulouse, France United Kingdom Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital Cambridge, England, United Kingdom Leeds Teaching Hosptials NHS Trust, Dept of Haematology Leeds, England, United Kingdom, LS9 7TF University Hospital Southampton NHS Foundation Trust Southampton, England, United Kingdom, SO16 6YD Cardiff and Vale Health Board, Clinical Research Facility Cardiff, United Kingdom, CF14 4XW University Hospitals of Leicester NHS Trust Leicester, United Kingdom, LE1 5WW The Christie NHS Foundation Trust Manchester, United Kingdom, M20 4BX Plymouth Hospitals NHS Trust Plymouth, United Kingdom, PL6 8BG 收起 <<
NCT03757000	B-cell Lymphoma Recurrent ... 展开 >> B-cell Chronic Lymphocytic Leukemia 收起 <<	Phase 1	Recruiting	May 30, 2019	China, Beijing ... 展开 >> Peking Cancer Hospital Recruiting Beijing, Beijing, China, 100142 Contact: Yuqin Song, MD,PhD 86 10-88140650 songyuqin622@163.com Contact: Meifeng Tu, MD,PhD 86 10-88121122 44329472@qq.com Principal Investigator: Yuqin Song, MD,PhD Sub-Investigator: Meifeng Tu, MD,PhD Sub-Investigator: Lingyan Ping, MD,PhD China, Jiangsu Jiangsu Province Hospital Not yet recruiting Nanjing, Jiangsu, China, 210029 Contact: Jiangyong Li, MD,PhD 86 25-83714511 lijianyonglm@126.com Contact: Wei Xu, MD,PhD 86 25-83714511 xuwei0484@jsph.org.cn Principal Investigator: Jianyong Li, MD,PhD Sub-Investigator: Meifeng Tu, MD,PhD China, Tianjin Hematology Hospital of Chinese Academy of Medical Sciences Recruiting Tianjin, Tianjin, China, 300020 Contact: Lugui Qiu, MD,PhD 86 22-23909172 qiulg@ihcams.ac.cn Contact: Junyuan Qi, MD,PhD 86 22-23909999 qijy@ihcams.ac.cn Principal Investigator: Lugui Qiu, MD,PhD Sub-Investigator: Junyuan Qi, MD,PhD 收起 <<
NCT02993536	-		Unknown	-	United States, Pennsylvania ... 展开 >> Abramson Cancer Center of the University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Anthony Mato, MD 855-216-0098 PennCancerTrials@emergingmed.com Principal Investigator: Anthony Mato, MD 收起 <<
NCT02332980	Recurrent Chronic Lymphocytic ... 展开 >>Leukemia Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Lymphoplasmacytic Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Nodal Marginal Zone Lymphoma Recurrent Small Lymphocytic Lymphoma Recurrent Splenic Marginal Zone Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Refractory Follicular Lymphoma Refractory Lymphoplasmacytic Lymphoma Refractory Nodal Marginal Zone Lymphoma Refractory Small Lymphocytic Lymphoma Refractory Splenic Marginal Zone Lymphoma Richter Syndrome Waldenstrom Macroglobulinemia 收起 <<	Phase 2	Recruiting	January 5, 2020	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Jose F. Leis United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Wei Ding 收起 <<
NCT02779283	Acute Lymphoblastic Leukemia ... 展开 >> Acute Myeloid Leukemia 收起 <<	Phase 1	Recruiting	June 1, 2019	United States, Oregon ... 展开 >> OHSU Knight Cancer Institute Recruiting Portland, Oregon, United States, 97239 Contact: Stephen E. Spurgeon 503-494-8950 spurgeos@ohsu.edu Principal Investigator: Stephen E. Spurgeon 收起 <<
NCT02824159	-		Recruiting	November 2020	France ... 展开 >> Cancer University Institute of Toulouse Oncopole Recruiting Toulouse, France, 31059 Contact: Guy Laurent, MD 5 31 15 62 09 ext +33 Laurent.guy@iuct-oncopole.fr Contact: Sandra Debaros 5.61.14.59.89 ext +33 debarros.s@chu-toulouse.fr 收起 <<
NCT02970318	Chronic Lymphocytic Leukemia	Phase 3	Recruiting	March 2020	United States, California ... 展开 >> Ventura County Hematology-Oncology Specialists Recruiting Oxnard, California, United States, 93030 United States, Illinois Joliet Oncology Hematology Associates, Ltd Recruiting Joliet, Illinois, United States, 60435 United States, Iowa Physicians Clinic of Iowa, P.C. Recruiting Cedar Rapids, Iowa, United States, 52403 United States, Kentucky Montgomery Cancer Center Recruiting Mount Sterling, Kentucky, United States, 40353 United States, Minnesota Coborn Cancer Center Recruiting Saint Cloud, Minnesota, United States, 56303 United States, Nebraska Nebraska Hematology-Oncology Recruiting Lincoln, Nebraska, United States, 68506 United States, New Jersey New Jersey Hematology / Oncology Associates Recruiting Bricktown, New Jersey, United States, 08724 United States, New York Hematology Oncology Associates of Rockland Recruiting Nyack, New York, United States, 10960 United States, Ohio Gabrail Cancer Center Recruiting Canton, Ohio, United States, 44718 United States, Texas Brooke Army Medical Center Recruiting Fort Sam Houston, Texas, United States, 78234 Baylor Scott & White Health Recruiting Round Rock, Texas, United States, 78665 收起 <<
NCT02787369	Recurrent Chronic Lymphoid Leu... 展开 >>kemia 收起 <<	Phase 1	Active, not recruiting	April 2022	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT02603445	Follicular Lymphoma, Mantle Ce... 展开 >>ll Lymphoma 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Novartis Investigative Site New York, New York, United States, 10017 United States, Texas Novartis Investigative Site Houston, Texas, United States, 77030 Austria Novartis Investigative Site Salzburg, Austria, 5020 France Novartis Investigative Site Pierre-Benite Cedex, France, 69495 Novartis Investigative Site Toulouse Cedex 9, France, 31059 Germany Novartis Investigative Site Freiburg, Germany, 79106 Novartis Investigative Site Mainz, Germany, 55131 收起 <<
NCT03701438	-		Enrolling by invitation	March 2020	France ... 展开 >> Centre Hospitalier Le Mans Le Mans, France, 72037 Centre Hospitalier Regional et Univeritaire de Tours Tours, France, 37044 Spain Hospital del Mar (Servei d'Hematologia Clinica) Barcelona, Spain, 08003 Hospital Universitario Ramon y Cajal Madrid, Spain, 28034 Hospital Son Llatzer Palma de Mallorca, Spain, 07198 收起 <<
NCT03469895	-		Active, not recruiting	July 2018	France ... 展开 >> Institut Paoli Calmettes Marseille, Bouches Du Rhone, France, 13009 收起 <<
NCT01732926	Indolent Non-Hodgkin's Lymphom... 展开 >>as 收起 <<	Phase 3	Terminated	-	-
NCT01088048	Indolent Non-Hodgkin's Lymphom... 展开 >>a Chronic Lymphocytic Leukemia Mantle Cell Lymphoma 收起 <<	Phase 1	Completed	-	United States, Alabama ... 展开 >> Clearview Cancer Institute Huntsville, Alabama, United States, 35805 United States, California UCLA Los Angeles, California, United States, 90024 Stanford Cancer Center Palo Alto, California, United States, 94304-5548 United States, Maryland Center for Cancer and Blood Disorders Bethesda, Maryland, United States, 20817 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New York Long Island Jewish Medical Center New Hyde Park, New York, United States, 11040 Weill Medical College of Cornell New York, New York, United States, 10021 United States, Oregon Willamette Valley Cancer Institute and Research Center Springfield, Oregon, United States, 97477 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Texas MD Anderson Cancer Houston, Texas, United States, 77030 United States, Washington North Star Lodge Cancer Center Yakima, Washington, United States, 98902 收起 <<
NCT01644799	Recurrent Follicular Lymphoma	Phase 1	Completed	-	United States, District of Col... 展开 >>umbia MedStar Georgetown University Hospital Washington, District of Columbia, United States, 20007 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New York Weill Medical College of Cornell University New York, New York, United States, 10065 United States, North Carolina University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27599 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT02136511	-		-	-	United States, California ... 展开 >> University of California, San Diego - Moores Cancer Center La Jolla, California, United States, 92093-0820 United States, District of Columbia Georgetown University Washington, District of Columbia, United States, 20007 United States, New Jersey Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 United States, New York Weill Cornell Medical College New York, New York, United States, 10021 Ireland St. James University Hospital Dublin, Ireland, 8 Italy Ospedale San Raffaele Milano, Italy, 20132 A.S.O. Molinette S. Giovanni Battista Turin, Italy, 10126 United Kingdom Hammersmith Hospital London, United Kingdom, W12 0HS 收起 <<
NCT02639910	Leukemia, Lymphocytic, Chronic... 展开 >>, B-Cell Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma 收起 <<	Phase 2	Active, not recruiting	-	United States, Florida ... 展开 >> Clinical Study Site Jacksonville, Florida, United States, 32204 United States, Minnesota Clinical Study Site Rochester, Minnesota, United States, 55905 United States, Ohio Clinical Study Site Columbus, Ohio, United States, 43210 Austria Clinical Study Site Graz, Austria, 8036 Clinical Study Site Salzburg, Austria, 5020 Clinical Study Site Wien, Austria, 1090 Germany Clinical Study Site Dresden, Germany, 1307 Clinical Study Site Leipzig, Germany, 4103 Clinical Study Site Muenchen, Germany, 80804 Italy Clinical Study Site Brescia, Italy, 25123 Clinical Study Site Milano, Italy, 20162 Poland Clinical Study Site Gdansk, Poland, 80952 Clinical Study Site Krakow, Poland, 30510 Clinical Study Site Lublin, Poland, 85094 Clinical Study Site Opole, Poland, 45372 United Kingdom Clinical Study Site Bournemouth, United Kingdom, BH7 7DW Clinical Study Site Leeds, United Kingdom, LS9 7TF 收起 <<
NCT01838434	Relapsed/Refractory Mantle Cel... 展开 >>l Lymphoma 收起 <<	Phase 1	Completed	-	United States, Illinois ... 展开 >> University of Chicago Chicago, Illinois, United States, 60637 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT03349346	Diffuse Large B-Cell Lymphoma ... 展开 >> Mediastinal B-cell Lymphoma 收起 <<	Phase 1	Withdrawn(The European Medical... 展开 >> Agency granted a Paediatric Investigational Product-specific waiver on the grounds that idelalisib is likely to be unsafe in paediatrics) 收起 <<	February 2026	France ... 展开 >> Centre Hospitalier Régional Universitaire de Lille Lille, France, 59000 Italy Istituto Giannina Gaslini Genova, Italy, 16147 Ospedale Pediatrico Bambino Gesu Roma, Italy, 00165 Infantile Regina Margherita Hospital Torino, Italy, 10126 Poland Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu Wrocław, Poland, 50-556 Spain Hospital Vall d´Hebrón Barcelona, Spain, 08035 Hospital Universitario HM Monteprincipe Madrid, Spain, 28660 收起 <<
NCT01569295	Chronic Lymphocytic Leukemia	Phase 3	Active, not recruiting	November 2018	-
NCT02968563	Chronic Lymphocytic Leukemia	Phase 2	Recruiting	February 2024	Germany ... 展开 >> Recruiting Mutlangen, Baden-Wuerttemberg, Germany Recruiting Ravensburg, Baden-Wuerttemberg, Germany Recruiting Tübingen, Baden-Württemberg, Germany Recruiting Ulm, Baden-Württemberg, Germany Recruiting Augsburg, Bavaria, Germany Recruiting München, Bavaria, Germany Recruiting Erlangen, Bayern, Germany Recruiting München, Bayern, Germany Recruiting Regensburg, Bayern, Germany Withdrawn Wurzburg, Bayern, Germany Recruiting Frankfurt, Brandenburg, Germany Recruiting Gießen, Hessen, Germany Recruiting Koln, Nordrhein-Westfalen, Germany Recruiting Mönchengladbach, Nordrhein-Westfalen, Germany Recruiting Paderborn, Nordrhein-Westfalen, Germany Recruiting Neunkirchen, Saarland, Germany Recruiting Leipzig, Sachsen, Germany Recruiting Kiel, Schleswig-Holstein, Germany Recruiting Luebeck, Germany Recruiting Mannheim, Germany Withdrawn Muenchen, Germany 收起 <<
NCT01980888	Chronic Lymphocytic Leukemia	Phase 3	Terminated	-	-
NCT03576443	Diffuse Large B Cell Lymphoma	Phase 2	Recruiting	July 1, 2022	Denmark ... 展开 >> Aarhus University Hospital Recruiting Aarhus C, Denmark, 8000 Contact: Judit Joergensen judijoer@rm.dk Sweden Halmstad County Hospital Recruiting Halmstad, Sweden, 30 233 Contact: Nevzeta Kuric nevzeta.kuric@regionhalland.se Linkoping University Hospital Recruiting Linköping, Sweden, 581 85 Contact: Ingemar Lagerlöf ingemar.lagerlof@regionostergotland.se Skane University Hospital Recruiting Lund, Sweden, 221 85 Contact: Karin Fjorden karin.fjorden@med.lu.se Karolinska University Hospital Recruiting Stockholm, Sweden, 141 86 Contact: Karin Ekstrom Smedby karin.ekstrom.smedby@ki.se 收起 <<
NCT01980888	-		Terminated	-	-
NCT03545035	-		Not yet recruiting	December 2019	-
NCT01980875	-		Terminated	-	-
NCT01732913	Indolent Non-Hodgkin's Lymphom... 展开 >>as 收起 <<	Phase 3	Terminated	-	-
NCT02962401	Waldenstrom Macroglobulinemia	Phase 2	Active, not recruiting	March 2025	France ... 展开 >> Project manager Tours, France, 37044 收起 <<
NCT01569295	-		Active, not recruiting	-	-
NCT01732913	-		Terminated	-	-
NCT02928510	Absence of Signs or Symptoms ... 展开 >> B-Cell Non-Hodgkin Lymphoma Digestive System Signs and Symptoms Indolent Adult Non-Hodgkin Lymphoma Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Chronic Lymphocytic Leukemia Recurrent Indolent Adult Non-Hodgkin Lymphoma Recurrent Small Lymphocytic Lymphoma 收起 <<	Not Applicable	Recruiting	February 1, 2029	United States, California ... 展开 >> UCLA / Jonsson Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90095 Contact: Daniel Hommes 310-206-5403 dhommes@mednet.ucla.edu Principal Investigator: Daniel Hommes 收起 <<
NCT02538614	Chronic Lymphocytic Leukemia (... 展开 >>CLL) 收起 <<	Phase 1	Terminated	-	United States, Ohio ... 展开 >> Ohio State University Columbus, Ohio, United States United States, Utah University of Utah Salt Lake City, Utah, United States 收起 <<
NCT01980875	Chronic Lymphocytic Leukemia	Phase 3	Terminated	-	United States, California ... 展开 >> Sansum Clinic Santa Barbara, California, United States, 93105 UCLA Jonsson Comprehensive Cancer Center Santa Monica, California, United States, 90404 Innovative Clinical Research Institute Whittier, California, United States, 90603 United States, Connecticut Cancer Center of Central Connecticut Southington, Connecticut, United States, 06489 United States, Ohio Gabrail Cancer Center Research Canton, Ohio, United States, 44718 United States, South Carolina Saint Francis Cancer Center Greenville, South Carolina, United States, 29607 Australia, New South Wales St Vincent Hospital, Sydney Darlinghurst, New South Wales, Australia, 2010 Belgium UZ Ghent- hematology Ghent, Belgium, 9000 Canada, Ontario Royal Victoria Regional Health Centre - Simcoe Musk Barrie, Ontario, Canada, L4M 6M2 France Centre Hospitalier du Mans Le Mans, France, 72037 Centre Hospitalier de Perpignan Perpignan Cedex 9, France, 66046-BP 49954 Poland Szpital Specjalistyczny w Brzozowie, Oddzial Hematologii Onkologicznej Brzozow, Podkarpackie, Poland, 36-200 Malopolskie Centrum Medyczne s.c. Krakow, Poland, 30-510 Wojewódzki Szpital Specjalistyczny w Legnicy Legnica, Poland, 59-220 Wojewodzki Szpital Specjalistyczny, im. M. Kopernika Klinika Hematologii Uniwersytetu Medycznego Lodz, Poland, 93-510 Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych z Warminsko-Mazurskim Centrum Onkologii w Olsztynie Oddzial Hematologii Olsztyn, Poland, 10-228 Spain Hospital Universitario de Salamanca Salamanca, Spain, 37007 United Kingdom East Kent Hospitals University NHS Foundation Trust Canterbury, Kent, United Kingdom, CT1 3NG 收起 <<
NCT02044822	-		Terminated	-	-
NCT01732926	-		Terminated	-	-
NCT02662296	Prolymphocytic Leukemia ... 展开 >> Recurrent Chronic Lymphocytic Leukemia Recurrent Non-Hodgkin Lymphoma Recurrent Small Lymphocytic Lymphoma 收起 <<	Phase 2	Withdrawn(Low enrollment)	-	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 收起 <<
NCT01539512	-		Completed	-	-
NCT02258529	-		Terminated	-	-
NCT01539512	Chronic Lymphocytic Leukemia	Phase 3	Completed	-	-
NCT02044822	B-cell Chronic Lymphocytic Leu... 展开 >>kemia (CLL) With 17p Deletion 收起 <<	Phase 2	Terminated	-	-
NCT03257722	Non Small Cell Lung Cancer ... 展开 >> Metastasis Recurrence 收起 <<	Phase 1 Phase 2	Recruiting	August 2021	United States, Georgia ... 展开 >> Georgia Cancer Center at Augusta University Recruiting Augusta, Georgia, United States, 30912 收起 <<
NCT02258529	Follicular Lymphoma ... 展开 >> Small Lymphocytic Lymphoma 收起 <<	Phase 2	Terminated	-	United States, California ... 展开 >> Pacific Shores Medical Group Long Beach, California, United States, 90813 United States, Florida Florida Cancer Specialists Fort Myers, Florida, United States, 33916 United States, Maryland St. Agnes Hospital Baltimore, Maryland, United States, 21229 United States, South Dakota Prarie Lakes Health Care Systems, Inc. Watertown, South Dakota, United States, 57201 United States, Tennessee Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37203 United States, Washington Northwest Medical Specialties, PLLC Tacoma, Washington, United States, 98405 收起 <<
NCT01203930	Chronic Lymphocytic Leukemia (... 展开 >>CLL) Small Lymphocytic Lymphoma (SLL) 收起 <<	Phase 2	Terminated	-	United States, California ... 展开 >> University of California, San Diego, Moores Cancer Center La Jolla, California, United States, 92093-0820 Stanford University School of Medicine Stanford, California, United States, 94304 United States, New York Columbia University - Herbert Irving Pavilion New York, New York, United States, 10032 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Texas The Universtity of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01796470	Chronic Lymphocytic Leukemia ... 展开 >> Mantle Cell Lymphoma Diffuse Large B-cell Lymphoma Indolent Non-Hodgkin's Lymphoma 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Marin Cancer Care Greenbrae, California, United States, 94904 UC San Diego Moores Cancer Center La Jolla, California, United States, 92093 Pacific Shores Medical Group Long Beach, California, United States, 90813 Ventura County Hematology Oncology Specialists Oxnard, California, United States, 93030 Cancer Center of Santa Barbara Santa Barbara, California, United States, 93105 United States, District of Columbia Georgetown University Medical Center Washington, District of Columbia, United States, 20007 United States, Florida Collaborative Research Group LLC Boynton Beach, Florida, United States, 33435 United States, Kentucky Montgomery Cancer Center Mount Sterling, Kentucky, United States, 40353 United States, New York New York University School of Medicine New York, New York, United States, 10016 Weill Cornell Medical College New York, New York, United States, 10021 University of Rochester, James P. Wilmot Cancer Center Rochester, New York, United States, 14642 United States, Ohio Signal Point Clinical Research Center, LLC Middletown, Ohio, United States, 45042 United States, Oregon Oregon Health and Science University Portland, Oregon, United States, 97239 United States, South Carolina Charleston Hematology Oncology Charleston, South Carolina, United States, 29414 Hollings Cancer Center Charleston, South Carolina, United States, 29425 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Utah Utah Cancer Specialists Salt Lake City, Utah, United States, 84106 United States, Washington Northwest Medical Specialties Tacoma, Washington, United States, 98405 收起 <<
NCT01539291	Chronic Lymphocytic Leukemia	Phase 3	Completed	-	-
NCT02468557	Pancreatic Ductal Adenocarcino... 展开 >>ma 收起 <<	Phase 1	Terminated	-	United States, Arizona ... 展开 >> Scottsdale Healthcare Clinical Research Institute Scottsdale, Arizona, United States, 85258 United States, California Cedars Sinai Medical Center Los Angeles, California, United States, 90048 United States, Colorado University of Colorado Cancer Center Aurora, Colorado, United States, 80045 United States, District of Columbia Georgetown University Washington, District of Columbia, United States, 20007 United States, Indiana Indiana University Goshen Center for Cancer Care Goshen, Indiana, United States, 46506 United States, Massachusetts Dana Farber/ Harvard Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York University of Rochester Rochester, New York, United States, 14642 United States, South Carolina Greenville Hospital System Greenville, South Carolina, United States, 29605 United States, Texas Mary Crowley Medical Research Center Dallas, Texas, United States, 75230 收起 <<
NCT02590588	-		Terminated(Poor accrual)	-	-
NCT01203930	-		Terminated	-	-
NCT01282424	-		Completed	-	-
NCT01282424	Follicular Lymphoma ... 展开 >> Small Lymphocytic Lymphoma Lymphoplasmacytic Lymphoma Marginal Zone Lymphoma 收起 <<	Phase 2	Completed	-	-
NCT01659021	Chronic Lymphocytic Leukemia	Phase 3	Completed	-	-
NCT02439138	Waldenstrom's Macroglobulinemi... 展开 >>a 收起 <<	Phase 2	Terminated(Safety issues from ... 展开 >>trials in CLL) 收起 <<	-	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT03639324	Chronic Lymphocytic Leukemia ... 展开 >> CLL Relapsed CLL Refractory Chronic Lymphocytic Leukemia Relapsed Chronic Lymphocytic Leukemia 收起 <<	Phase 1	Not yet recruiting	September 30, 2025	United States, Virginia ... 展开 >> Virginia Commonwealth University/ Massey Cancer Center Not yet recruiting Richmond, Virginia, United States, 23298 Contact: Yazbeck Y Victor, MD, MS 804-628-2073 victor.yazbeck@vcuhealth.org Contact: Caryn R Weir, RN, M.P.H. 804-628-2310 cweir@vcu.edu 收起 <<
NCT02590588	Amyloidosis	Phase 2	Terminated(Poor accrual)	-	United States, Massachusetts ... 展开 >> Boston Medical Center Boston, Massachusetts, United States, 02118 收起 <<
NCT03568929	-		Recruiting	November 2020	Austria ... 展开 >> Landeskrankenhaus Steyr Not yet recruiting Steyr, Austria France Centre Hospitalier Universitaire d'Amiens (CHU d'Amiens) - Hopital Nord Not yet recruiting Amiens Cedex 1, France, 80054 Centre Hospitalier Bourg-en-Bresse Fleyriat Recruiting Bourg-en-Bresse, France CHU de Dijon Not yet recruiting Bourgogne, France, 2100 Centre Hospitalier de Cannes Not yet recruiting Cannes, France, 06400 Hôpital Privé Sévigné Not yet recruiting Cesson-Sévigné, France Centre Hospitalier Chalon sur Saône William Morey Recruiting Chalon-Sur-Saone, France, 71100 Centre Hospitalier Universitaire Estaing Not yet recruiting Clermont-Ferrand, France, 63003 Groupe Hospitalier Mutualiste de Grenoble - Institut Daniel Hollard Recruiting Grenoble, France Clinique Victor Hugo Not yet recruiting Le Mans Cedex 2, France Centre Hospitalier Le Mans Not yet recruiting Le Mans, France, 72037 Centre Hospitalier de Lens Not yet recruiting Lens, France, 62300 Centre Hospitalier Régional d'Orléans Recruiting Orléans, France, 45650 Centre hospitalier de Perigueux Not yet recruiting Pessac, France, 33604 Germany Klinikum Frankfurt Hochst Not yet recruiting Frankfurt, Germany, 65929 Klinikum Südstadt Rostock Not yet recruiting Rostock, Germany Gemeinschaftspraxis für Hämatologie und Onkologie Westerstede Recruiting Westerstede, Germany, 26655 Ireland Midland Regional Hospital - Mullingar Not yet recruiting Mullingar, Ireland Italy Ospedali Riuniti di Ancona, Clinica Ematologica Not yet recruiting Ancona, Italy, 60126 Ospedale Mazzoni Recruiting Ascoli Piceno, Italy Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Not yet recruiting Brescia, Italy Azienda Ospedaliera Universitaria Maggiore Della Carita di Novara Recruiting Novara, Italy, 28100 Ospedale Casa Sollievo della Sofferenza Not yet recruiting San Giovanni Rotondo, Italy, 71013 Spain Hospital Universitario Son Dureta Not yet recruiting Palma de Mallorca, Spain Clínica Universidad de Navarra Not yet recruiting Pamplona, Spain 收起 <<
NCT02739360	Lymphoid Malignancies	Phase 4	Completed	-	Netherlands ... 展开 >> Amsterdam, Netherlands 收起 <<
NCT02439138	-		Terminated(Safety issues from ... 展开 >>trials in CLL) 收起 <<	-	-
NCT01090414	Chronic Lymphocytic Leukemia ... 展开 >> Lymphoma, Non-Hodgkin 收起 <<	Phase 1	Completed	-	United States, Alabama ... 展开 >> Clearview Cancer Institute Huntsville, Alabama, United States, 35805 United States, California UCLA Los Angeles, California, United States, 90095-1678 Stanford Cancer Center Palo Alto, California, United States, 94304-5548 United States, Maryland Center for Cancer & Blood Disorders, PC Bethesda, Maryland, United States, 20817 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New York Long Island Jewish medical Center New Hyde Park, New York, United States, 11042 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Weill Medical College of Cornell New York, New York, United States, 10021 Mount Sinai School of Medicine New York, New York, United States, 10029 United States, Ohio The Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Oregon Oregon Health & Science University Portland, Oregon, United States, 97239 Willamette Valley Cancer Institute and Research Center Springfield, Oregon, United States, 97477 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Texas MD Anderson Cancer and Research Center Houston, Texas, United States, 77030 MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Washington Yakima Regional Cancer Care Yakima, Washington, United States, 98902 United States, Wisconsin University of Wisconsin Madison, Wisconsin, United States, 53792-5156 收起 <<
NCT02135133	Chronic Lymphocytic Leukemia ... 展开 >> Small Lymphocytic Lymphoma 收起 <<	Phase 2	Active, not recruiting	March 2021	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Isreal Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT02536300	Follicular Lymphoma	Phase 3	Recruiting	May 2023	-
NCT03742323	Acute Lymphoblastic Leukemia	Phase 1 Phase 2	Recruiting	January 1, 2022	Spain ... 展开 >> Complejo Hospitalario A Coruña Recruiting A Coruña, Spain Contact: Guillermo Deben, Dr + 34 981 17 80 00 guillermo.deben.ariznavarreta@sergas.es Hospital ICO Badalona Recruiting Badalona, Spain Contact: José María Ribera, Dr + 34 934 978 987 jribera@iconcologia.net Hospital Clinic de Barcelona Recruiting Barcelona, Spain Contact: Jordi Esteve, Dr +34 93 227 54 00 jesteve@clinic.cat Hospital Vall d'Hebrón Recruiting Barcelona, Spain Contact: Pere Barba, Dr + 34 934 89 30 00 pbarba@vhio.net Hospital ICO Hospitalet Recruiting Hospitalet de Llobregat, Spain Contact: Santiago Mercadal, Dr + 34 932 607 733 smercadal@iconcologia.net Hospital 12 de Octubre Recruiting Madrid, Spain Contact: Mª Pilar Martínez, Dr + 34 91 508 57 31 mariapilar.martinez.sanchez@salud.madrid.org H. Morales Meseguer Recruiting Murcia, Spain Contact: Mª Luz Amigo, Dr + 34 968 36 09 00 mluzamigo@yahoo.com H. Virgen de la Victoria Recruiting Mála, Spain Contact: Mª José Moreno, Dr + 34 951 03 20 00 mjmorenorico@hotmail.com Hospital Clinico de Salamanca Recruiting Salamanca, Spain Contact: Jesús María Hernández-Rivas, Dr +34 923 291384 jaher@usal.es Hospital Marques de Valdecilla Recruiting Santander, Spain Contact: Arancha Bermúdez, Dr + 34 942 20 25 20 abermudez@valdecilla.com H. Universitario Virgen de Rocío Recruiting Sevilla, Spain Contact: José González-Campos, Dr + 34 955012218 jgonzalez@rocio.es Hospital Universitario y Politécnico la Fe Recruiting Valencia, Spain Contact: Pau Montesinos, Dr +34 963 86 27 00 montesinos_pau@gva.es 收起 <<
NCT02436135	Myelofibrosis	Phase 1	Completed	-	United States, California ... 展开 >> Stanford Hospital and Clinics Stanford, California, United States, 94305 United States, Michigan University of Michigan Health System Ann Arbor, Michigan, United States, 48109 收起 <<
NCT01659021	-		Completed	-	-
NCT01306643	-		Completed	-	-
NCT01306643	Indolent Non-Hodgkin's Lymphom... 展开 >>a Follicular Lymphoma Small Lymphocytic Lymphoma Marginal Zone Lymphoma 收起 <<	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> Stanford Cancer Center Palo Alto, California, United States, 94304-5548 United States, New York Mount Sinai School of Medicine New York, New York, United States, 10029 收起 <<
NCT03151057	B Cells-Tumors ... 展开 >> B Cell Chronic Lymphocytic Leukemia Follicular Lymphoma Mantle Cell Lymphoma Large B-Cell Diffuse Lymphoma of Bone (Diagnosis) 收起 <<	Phase 1	Recruiting	December 2020	United States, Maryland ... 展开 >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21205 Contact: Douglas Gladstone, MD 410-955-8781 dgladst1@jhmi.edu Contact: Mary A Stevens, MD 443-287-0180 msteve35@jhmi.edu 收起 <<
NCT03582098	-		Recruiting	December 2018	Ireland ... 展开 >> St James Hospital Recruiting Dublin, Ireland, 8 United Kingdom NHS Grampian Recruiting Aberdeen, United Kingdom, AB25 2ZN University Hospital of Wales Not yet recruiting Cardiff, United Kingdom, CF14 4XW Cheltenham General Hospital Recruiting Cheltenham, United Kingdom, GL53 7AN London Northwest University NHS Trust Recruiting Eastcote, United Kingdom, HA4 8PD Milton Keynes University Hospital Not yet recruiting Milton Keynes, United Kingdom, MK6 5LD Oxford University Hospitals NHS Trust Recruiting Oxford, United Kingdom, OX3 7LE Whiston Hospital - St Helens And Knowsley Teaching Hospitals NHS Trust Recruiting Prescot, United Kingdom, L35 5DR Southend University Hospital NHS Foundation Trust Recruiting Southend-On-Sea, United Kingdom, SS0 0RY Singleton Hospital Not yet recruiting Swansea, United Kingdom, SA2 8QA Royal Cornwall Hospital Recruiting Truro, United Kingdom, TR1 3LJ Worcestershire Royal Hospital Recruiting Worcester, United Kingdom, WR5 1DD 收起 <<
NCT00710528	Chronic Lymphocytic Leukemia (... 展开 >>CLL) Lymphoma, Non-Hodgkin (NHL) Acute Myeloid Leukemia (AML) Multiple Myeloma (MM) 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> Stanford Cancer Center Palo Alto, California, United States, 94304-5548 United States, Maryland The Sidney Kimmel Comprehensive Cancer Center at John Hopkins Baltimore, Maryland, United States, 21231 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Missouri Washington University School of Medicine St. Louis, Missouri, United States, 63110 United States, New York Weill Medical College of Cornell New York, New York, United States, 10021 United States, Ohio The Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Oregon Oregon Health and Science University Portland, Oregon, United States, 97239-3098 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Wisconsin University of Wisconsin Madison, Wisconsin, United States, 53792-5156 收起 <<
NCT01659047	Chronic Lymphocytic Leukemia	Phase 2	Withdrawn	December 2015	-
NCT01393106	-		Completed	-	-
NCT03133221	Non Hodgkin Lymphoma ... 展开 >> Follicular Lymphoma Indolent Lymphoma B-cell Lymphoma Transformed Lymphoma Marginal Zone Lymphoma Waldenstrom Macroglobulinemia Small Lymphocytic Lymphoma Lymphoplasmacytic Lymphoma 收起 <<	Phase 2	Recruiting	March 2022	United States, Maryland ... 展开 >> Greenebaum Cancer Center at University of Maryland Medical Center Recruiting Baltimore, Maryland, United States, 21201-1592 Contact: Sunita Philip, MPH, CCRP 410-328-8199 sphilip1@umm.edu Contact: Carolynn G. Harris, BA, CCRP 410-328-8198 charris@umm.edu United States, Missouri Washington University School of Medicine Not yet recruiting Saint Louis, Missouri, United States, 63110 Contact: Amanda Cashen, MD 314-454-8306 acashen@DOM.wustl.edu United States, Virginia Virginia Commonwealth University Not yet recruiting Richmond, Virginia, United States, 23298 Contact: Victor Yazbeck, MD 804-628-2073 vyyazbeck@vcu.edu 收起 <<
NCT01393106	Hodgkin Lymphoma	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109 收起 <<
NCT02445131	Chronic Lymphocytic Leucemia	Phase 2	Recruiting	May 2020	Germany ... 展开 >> German CLL Study Group Recruiting Cologne, Germany, 50935 Contact: Paula Cramer, Dr. med. 0221 478 88220 paula.cramer@uk-koeln.de Contact: Julia von Tresckow, Dr. med. 0221 478 88220 julia.von-tresckow@uk-koeln.de 收起 <<
NCT02242045	Chronic Lymphocytic Leukemia ... 展开 >> Indolent Non-Hodgkin Lymphoma Follicular Lymphoma Small Lymphocytic Lymphoma Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia) Marginal Zone Lymphoma 收起 <<	Phase 1	Completed	-	Japan ... 展开 >> Miyagi, Japan Nagoya, Japan Sendai, Japan Tokyo, Japan 收起 <<
NCT00836914	Allergic Rhinitis	Phase 1	Completed	-	Austria ... 展开 >> Vienna Challenge Chamber Vienna, Austria 收起 <<

CCRF-SB	1 μM	Function Assay	24 h	Induction of apoptosis	20959606
CLL PBMCs		Growth Inhibition Assay		IC50=2.9 nM	25917267
DERL7	10 μM	Growth Inhibition Assay	72 h	does not induce apoptosis	22801959
Granta-519	1 μM	Function Assay	2 h	Inhibition of Akt(t308) phosphorylation	23341541
Granta-519	1 μM	Function Assay	2 h	Inhibition of Akt(s473) phosphorylation	23341541
HH	10 μM	Growth Inhibition Assay	72 h	Induction of apoptosis slightly	22801959
HuT78	10 μM	Growth Inhibition Assay	72 h	does not induce apoptosis	22801959
INA-6	5 μM	Function Assay	6 h	Inhibition of PI3K/Akt and ERK pathway	20505158
JEKO-1	1 μM	Function Assay	72 h	Inhibition of Akt phosphorylation in IgM-stimulated JEKO-1	23341541
JEKO-1	10 μM	Growth Inhibition Assay	72 h	Inhibition of proliferation slightly	23341541
JEKO-1	5 μM	Growth Inhibition Assay	72 h	does not induce cell cycle arrest or apoptosis	23676220
K562	1 μM	Function Assay	3 h	Inhibition of Akt phosphorylation	25014775
K562	1 μM	Function Assay	3 h	Inhibition of P70S6K phosphorylation	25014775
K562	1 μM	Function Assay	3 h	Inhibition of GSK3 phosphorylation	25014775
K562	1 μM	Growth Inhibition Assay	72 h	Inhibition of proliferation	25014775
KMH-2	10 μM	Function Assay	2 h	Inhibition of Akt phosphorylation	22210877
L1236	10 μM	Function Assay	2 h	Inhibition of Akt phosphorylation	22210877
L1236	5 μM	Function Assay	24 h	Blocks secretion of the CCL5	22210877
L1236	5 μM	Apoptosis Assay	24 h	Induction of apoptosis	22210877
L428	10 μM	Function Assay	2 h	Inhibition of Akt phosphorylation	22210877
L591	10 μM	Function Assay	2 h	Inhibition of Akt phosphorylation	22210877
L591	5 μM	Function Assay	24 h	Blocks secretion of the CCL5	22210877
L591	5 μM	Apoptosis Assay	24 h	Induction of apoptosis	22210877
LB	5 μM	Function Assay	6 h	Inhibition of PI4K/Akt and ERK pathway	20505158
MAVER-1	5 μM	Growth Inhibition Assay	72 h	does not induce cell cycle arrest or apoptosis	23676220
MEC1		Growth Inhibition Assay		IC50=20.4 μM	25999352
Microglia	5 μM	Function Assay	10 h	Decrease of TNFa secretion from LPS-stimulated p110δD910A/D910A microglia	24625684
MINO	5 μM	Growth Inhibition Assay	72 h	does not induce cell cycle arrest or apoptosis	23676220
MJ	10 μM	Growth Inhibition Assay	72 h	does not induce apoptosis	22801959
Myla	10 μM	Growth Inhibition Assay	72 h	does not induce apoptosis	22801959
Primary AML cell	1 μM	Function Assay	3 h	Inhibition of Akt phosphorylation	25014775
Primary AML cell	1 μM	Function Assay	3 h	Inhibition of P70S6K phosphorylation	25014775
Primary AML cell	1 μM	Function Assay	3 h	Inhibition of GSK3 phosphorylation	25014775
Primary AML cell	1 μM	Growth Inhibition Assay	3 h	Suppression of rRNA synthesis	25014775
Primary CLL cell	1 μM	Function Assay	15 min	Blocks BCR-induced LCP1 serine-5 activation	24009233
SK-MG3	5 μM	Function Assay	24 h	Inhibition of Akt phosphorylation substantially	22079609
SP53	0.1 μM	Growth Inhibition Assay	72 h	does not induce cell cycle arrest or apoptosis	23676220
SR786	10 μM	Growth Inhibition Assay	72 h	does not induce apoptosis	22801959
SU-DHL-5	1 μM	Function Assay	24 h	Induction of apoptosis	20959606
SW1783	100 nM	Function Assay	24 h	Inhibition of cell migration	22079609
SW1783	5 μM	Function Assay	24 h	Inhibition of Akt phosphorylation substantially	22079609
U266	40 μM	Growth Inhibition Assay	48 h	79.5% inhibition rate	25339332
U-373MG	5 μM	Function Assay	24 h	Inhibition of Akt phosphorylation substantially	22079609
U-87MG	100 nM	Function Assay	24 h	Inhibition of cell migration	22079609
U-87MG	5 μM	Function Assay	24 h	Inhibition of Akt phosphorylation substantially	22079609
WSU-NHL	1 μM	Function Assay	24 h	Induction of apoptosis	20959606

Idelalisib/艾代拉里斯 {[allProObj[0].p_purity_real_show]}

Idelalisib/艾代拉里斯纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Idelalisib/艾代拉里斯质控信息

Idelalisib/艾代拉里斯生物活性

Idelalisib/艾代拉里斯细胞实验

Idelalisib/艾代拉里斯动物实验

Idelalisib/艾代拉里斯动物研究

Idelalisib/艾代拉里斯临床研究

Idelalisib/艾代拉里斯参考文献

Idelalisib/艾代拉里斯实验方案

Idelalisib/艾代拉里斯技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Idelalisib/艾代拉里斯 {[allProObj[0].p_purity_real_show]}

Idelalisib/艾代拉里斯 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Idelalisib/艾代拉里斯 质控信息

Idelalisib/艾代拉里斯 生物活性

Idelalisib/艾代拉里斯 细胞实验

Idelalisib/艾代拉里斯 动物实验

Idelalisib/艾代拉里斯 动物研究

Idelalisib/艾代拉里斯 临床研究

Idelalisib/艾代拉里斯 参考文献

Idelalisib/艾代拉里斯 实验方案

Idelalisib/艾代拉里斯 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Idelalisib/艾代拉里斯纯度/质量文件产品仅供科研

Idelalisib/艾代拉里斯质控信息

Idelalisib/艾代拉里斯生物活性

Idelalisib/艾代拉里斯细胞实验

Idelalisib/艾代拉里斯动物实验

Idelalisib/艾代拉里斯动物研究

Idelalisib/艾代拉里斯临床研究

Idelalisib/艾代拉里斯参考文献

Idelalisib/艾代拉里斯实验方案

Idelalisib/艾代拉里斯技术信息